Fiamma Berner

Kantonsspital St. Gallen
Sankt Gallen, SG 9007, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Autoimmunity Against Surfactant Protein B Is Associated with Pneumonitis During Checkpoint Blockade.

Autoimmunity Against Surfactant Protein B Is Associated with Pneumonitis During Checkpoint Blockade.

Journal: American journal of respiratory and critical care medicine

Published: April 16, 2024

A replicating LCMV-based vaccine for the treatment of solid tumors.

A replicating LCMV-based vaccine for the treatment of solid tumors.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: April 17, 2023

Autoreactive T cells targeting type II pneumocyte antigens in COVID-19 convalescent patients.

Autoreactive T cells targeting type II pneumocyte antigens in COVID-19 convalescent patients.

Journal: Journal of autoimmunity

Published: March 09, 2023

Autoimmunity in immune checkpoint inhibitor-induced immune-related adverse events: A focus on autoimmune skin toxicity and pneumonitis.

Autoimmunity in immune checkpoint inhibitor-induced immune-related adverse events: A focus on autoimmune skin toxicity and pneumonitis.

Journal: Immunological reviews

Published: February 28, 2023

Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors.

Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors.

Journal: Med (New York, N.Y.)

Published: November 29, 2022

Autoreactive napsin A-specific T cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockade.

Autoreactive napsin A-specific T cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockade.

Journal: Science immunology

Published: September 02, 2022

C reactive protein flare predicts response to checkpoint inhibitor treatment in non-small cell lung cancer.

C reactive protein flare predicts response to checkpoint inhibitor treatment in non-small cell lung cancer.

Journal: Journal for immunotherapy of cancer

Published: February 14, 2022

Keratinocyte differentiation antigen-specific T cells in immune checkpoint inhibitor-treated NSCLC patients are associated with improved survival.

Keratinocyte differentiation antigen-specific T cells in immune checkpoint inhibitor-treated NSCLC patients are associated with improved survival.

Journal: Oncoimmunology

Published: December 03, 2021

Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients.

Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients.

Journal: Journal of cancer research and clinical oncology

Published: July 26, 2021

Preexisting and Post-COVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer.

Preexisting and Post-COVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer.

Journal: Cancer discovery

Published: February 12, 2021

Fingolimod and tumor-infiltrating lymphocytes in checkpoint-inhibitor treated cancer patients.

Fingolimod and tumor-infiltrating lymphocytes in checkpoint-inhibitor treated cancer patients.

Journal: Cancer immunology, immunotherapy : CII

Published: March 05, 2020

Immune-Related Adverse Events of Immune Checkpoint Inhibitors-From a Clinical to Pathophysiological View-In Reply.

Immune-Related Adverse Events of Immune Checkpoint Inhibitors-From a Clinical to Pathophysiological View-In Reply.

Journal: JAMA oncology

Published: October 04, 2019

Showing 1-12 of 19

Last Updated: 09/26/2026